登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《Lancet，6月19日，Feasibility and physiological effects of prone positioning in non-intubated patients with acute respiratory failure due to COVID-19 (PRON-COVID): a prospective cohort study》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-06-20

  • Feasibility and physiological effects of prone positioning in non-intubated patients with acute respiratory failure due to COVID-19 (PRON-COVID): a prospective cohort study

    Anna Coppo, MD

    Giacomo Bellani, MD

    Dario Winterton, MD

    Michela Di Pierro, MD

    Alessandro Soria, MD

    Paola Faverio

    et al.

    Show all authors

    Published:June 19, 2020DOI:https://doi.org/10.1016/S2213-2600(20)30268-X

    Summary

    Background

    The COVID-19 pandemic is challenging advanced health systems, which are dealing with an overwhelming number of patients in need of intensive care for respiratory failure, often requiring intubation. Prone positioning in intubated patients is known to reduce mortality in moderate-to-severe acute respiratory distress syndrome. We aimed to investigate feasibility and effect on gas exchange of prone positioning in awake, non-intubated patients with COVID-19-related pneumonia.

    Methods

    In this prospective, feasibility, cohort study, patients aged 18–75 years with a confirmed diagnosis of COVID-19-related pneumonia receiving supplemental oxygen or non-invasive continuous positive airway pressure were recruited from San Gerardo Hospital, Monza, Italy. We collected baseline data on demographics, anthropometrics, arterial blood gas, and ventilation parameters. After baseline data collection, patients were helped into the prone position, which was maintained for a minimum duration of 3 h. Clinical data were re-collected 10 min after prone positioning and 1 h after returning to the supine position. The main study outcome was the variation in oxygenation (partial pressure of oxygen [PaO2]/fractional concentration of oxygen in inspired air [FiO2]) between baseline and resupination, as an index of pulmonary recruitment. This study is registered on ClinicalTrials.gov, NCT04365959, and is now complete.

  • 原文来源：https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30268-X/fulltext
73浏览量
原文链接
相关报告

  • 《LANCET，5月7日，COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-05-09
    • Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study Giulio Cavalli, MD Giacomo De Luca, MD Corrado Campochiaro, MD Emanuel Della-Torre, MD Marco Ripa, MD Diana Canetti, MD et al. Show all authors Published:May 07, 2020DOI:https://doi.org/10.1016/S2665-9913(20)30127-2 Background Mortality of patients with coronavirus disease 2019 (COVID-19), acute respiratory distress syndrome (ARDS), and systemic inflammation is high. In areas of pandemic outbreak, the number of patients can exceed maximum capacity of intensive care units (ICUs), and, thus, these individuals often receive non-invasive ventilation outside of the ICU. Effective treatments for this population are needed urgently. Anakinra is a recombinant interleukin-1 receptor antagonist that might be beneficial in this patient population.
    43浏览量
    原文链接

  • 《Lancet，5月28日，Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-05-29
    • Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study Nicole M Kuderer, MD † Toni K Choueiri, MD † Dimpy P Shah, PhD † Yu Shyr, PhD † Samuel M Rubinstein, MD Donna R Rivera, PharmD et al. Published:May 28, 2020DOI:https://doi.org/10.1016/S0140-6736(20)31187-9 Summary Background Data on patients with COVID-19 who have cancer are lacking. Here we characterise the outcomes of a cohort of patients with cancer and COVID-19 and identify potential prognostic factors for mortality and severe illness. Methods In this cohort study, we collected de-identified data on patients with active or previous malignancy, aged 18 years and older, with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection from the USA, Canada, and Spain from the COVID-19 and Cancer Consortium (CCC19) database for whom baseline data were added between March 17 and April 16, 2020. We collected data on baseline clinical conditions, medications, cancer diagnosis and treatment, and COVID-19 disease course. The primary endpoint was all-cause mortality within 30 days of diagnosis of COVID-19. We assessed the association between the outcome and potential prognostic variables using logistic regression analyses, partially adjusted for age, sex, smoking status, and obesity. This study is registered with ClinicalTrials.gov, NCT04354701, and is ongoing.
    139浏览量
    原文链接